Nuvation Bio Q2 2024 GAAP EPS $(1.89) May Not Be Comparable To $(0.06) Estimate, Sales $1.435M
Portfolio Pulse from Benzinga Newsdesk
Nuvation Bio reported its Q2 2024 GAAP EPS at $(1.89), which is significantly lower than the $(0.06) estimate. The company also reported sales of $1.435 million.
August 05, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Nuvation Bio's Q2 2024 GAAP EPS of $(1.89) is significantly below the $(0.06) estimate, indicating a substantial earnings miss. The company also reported sales of $1.435 million.
The significant miss on EPS compared to estimates is likely to negatively impact investor sentiment and the stock price in the short term. The reported sales figure, while positive, is overshadowed by the large earnings miss.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100